In a landmark announcement, the World Health Organization (WHO) has recommended the use of the first-ever malaria vaccine for children. WHO Director-General Tedros Adhanom Ghebreyesus endorsed the RTS,S/AS01 malaria or Mosquirix – a vaccine developed by British drugmaker GlaxoSmithKline (GSK).
The WHO has recommended extensive use of the RTS,S/AS01 vaccine among children in Sub-Saharan Africa and other regions with moderate to high malaria transmission. The vaccine acts against the deadliest malaria transmission parasite, P. falciparum, which is prevalent in Africa. The symptoms of malaria are–fever, headaches, and muscle pain, then cycles of chills, fever, and sweating.
According to Tedros, ” RTS,S malaria vaccine – more than 30 years in the making – changes the course of public health history. This vaccine is a gift to the world”.
The WHO said in a statement it was recommending the widespread application of the vaccine among children in sub-Saharan Africa and other regions with moderate to high malaria transmission.
Many vaccines exist against viruses and bacteria, but this was the first time that the WHO recommended broad use of a vaccine against a human parasite.
According to the latest World Malaria Report, there were an estimated 229 million cases of malaria globally in 2019, with the WHO African region accounting for 94 per cent of all cases and deaths.
A child under five years old dies of malaria every two minutes, according to UNICEF estimates, while WHO says that malaria is responsible for 260,000 deaths each year in children under five in Africa.
The third phase of clinical trials revealed that the vaccine was 50 per cent efficacious in preventing malaria in children aged between five and 17 months. The vaccine is given in three doses between these ages, with a fourth dose about 18 months later.
According to Reuters news agency, experts said the challenge now would be mobilising financing for production and distribution of the vaccine. GSK has to date committed to producing 15 million doses of Mosquirix annually up to 2028 at a cost of production plus no more than 5% margin.
A global market study led by the WHO this year projected demand for a malaria vaccine would be 50 to 110 million doses per year by 2030 if it is deployed in areas with moderate to high transmission of the disease.
Resources:
https://www.livemint.com/science/health/who-approves-world-s-first-malaria-vaccine-11633573233450.html
In the second half of 2022, China unveiled the details of its data export regulations, providing further explanations to its existing laws and regulations on data.
The current energy crisis has reached an unsustainable level for the European chemical industry. For the first time ever, the EU imports more chemicals than it exports, both in volume and value, resulting in a trade deficit of € 5.6 bn for the first half of 2022.
Endocrine Disrupting Chemicals (also referred to as hormone disruptors or EDCs) are synthetic chemicals that are not produced by the human body and that disrupt the normal functioning of humans and animals.
The shipping industry is now returning to normality and is in a downward spiral. The cost of shipping goods from China has slumped to the lowest level in more than two years as the world economy stumbles, dimming prospects for container carriers that turned in record profits during the pandemic.
No precipitous plunge in container shipping rates, just ‘orderly’ decline.
The global food and beverage market size is expected to grow from $5.8 trillion in 2021 to $6.4 trillion in 2022 at a growth rate of 9.7%. The food and beverage market size is expected to grow to $8.9 trillion in 2026 at a compound annual growth rate of 8.7%.
The amendment makes QR codes mandatory on every active pharmaceutical ingredient. The Amendment Rules will come into force from January 01, 2023.
On June 22, 2022, the Commission adopted pioneering proposals to restore damaged ecosystems and bring nature back across Europe, from agricultural land and seas, to forests and urban environments. The Commission also proposes to reduce the use and risk of chemical pesticides by 50% by 2030.
According to New York Times, in a small clinical trial, 18 patients took a drug called Dostarlimab for around six months, and in the end, every one of them saw their tumours disappear.